GLP-1 agonists reduce risk of Stroke and provide neuroprotection to diabetes patients
Neuroprotective effects of glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are independent of glycemic control, says an article published in Journal of Diabetes and its Complications.
Stroke accounts for 11.6% of all fatalities globally, making it the second leading cause of death. In 2019, there were about 6.55 million stroke-related fatalities, 12.2 million incident cases, and 101 million prevalent cases. Stroke risk is often increased in diabetic patients. In recent years, new glucose-lowering medications have been launched, and randomized controlled trials (RCTs) have shown the varied effects of these medications on cardiovascular end events. Jiaxi Li and his colleagues did a meta-analysis to incorporate these trials, which employed SGLT-2 inhibitors, GLP-1 agonists, or DPP-4 inhibitors in the experimental group and placebo in the control group to evaluate the influence on the risk of stroke in people with type 2 diabetes.
Studies having stroke as an outcome event up to 3 December 2021 were found through searches of the Embase, Cochrane Library, and PubMed databases. A fixed-effects model was used to examine risk ratios for outcomes related to stroke.
The key findings of this study were:
19 RCTs involving 155 027 type 2 diabetic individuals were discovered.
According to a pooled analysis, GLP-1 agonists decreased total stroke (RR = 0.84, 95%CI 0.77-0.93, P = 0.000, I2 = 0%) and non-fatal stroke (RR = 0.85, 95%CI 0.77-0.94, P = 0.002, I2 = 0%) by 16% and 15%, respectively, compared to placebo.
Neither SGLT-2 inhibitors nor DPP-4 inhibitors were substantially linked to a reduced risk of stroke.
In conclusion, if GLP-1 agonists are to be utilized to lower the risk of stroke in people with type 2 diabetes, more research is required. Additionally, more study is required to determine how various stroke subtypes are affected by novel glucose-lowering medications.
Reference:
Li, J., Ji, C., Zhang, W., Lan, L., & Ge, W. (2023). Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. In Journal of Diabetes and its Complications (Vol. 37, Issue 1, p. 108362). Elsevier BV. https://doi.org/10.1016/j.jdiacomp.2022.108362
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.